Condition
Resistant Cancer
Total Trials
7
Recruiting
3
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
14.3%
1 terminated out of 7 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
6Total
Not Applicable (2)
P 1 (3)
P 2 (1)
Trial Status
Recruiting3
Terminated1
Unknown1
Active Not Recruiting1
Not Yet Recruiting1
Clinical Trials (7)
Showing 7 of 7 trials
NCT05718882Not ApplicableTerminated
Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC
NCT06347068Phase 1Recruiting
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
NCT07535840Not ApplicableNot Yet Recruiting
A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
NCT06158139Phase 1Recruiting
Autologous CAR-T Cells Targeting B7-H3 in PDAC
NCT05889312Recruiting
Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET
NCT03678883Phase 2Active Not Recruiting
9-ING-41 in Patients with Advanced Cancers
NCT04292119Phase 1Unknown
Lorlatinib Combinations in Lung Cancer
Showing all 7 trials